Combined effect of telmisartan and fluvastatin on arachidonic acid metabolism in human liver microsomes

References

• Ai D, Pang W, Li N, et al. (2009). Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci USA 106:564–9.
   PubMed Web of Science ®Google Scholar
• Andersson TB, Bredberg E, Ericsson H, et al. (2004). An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metab Dispos 32:715–21.
   PubMed Web of Science ®Google Scholar
• Appel S, Rüfenacht T, Kalafsky G, et al. (1995). Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am J Cardiol 76:29A–32A.
   PubMed Web of Science ®Google Scholar
• Arima S, Endo Y, Yaoita H, et al. (1997). Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 100:2816–23.
   PubMed Web of Science ®Google Scholar
• Börgel J, Bulut D, Hanefeld C, et al. (2008). The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile. BMC Cardiovasc Disord 8:41.
   PubMed Web of Science ®Google Scholar
• Campbell WB, Gebremedhin D, Pratt PF, et al. (1996). Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78:415–23.
   PubMed Web of Science ®Google Scholar
• Chou TC. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621–81.
   PubMed Web of Science ®Google Scholar
• Delaney WE, Yang H, Miller MD, et al. (2004). Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 48:3702–10.
   PubMed Web of Science ®Google Scholar
• Fischer V, Johanson L, Heitz F, et al. (1999). The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 27:410–16.
   PubMed Web of Science ®Google Scholar
• Imig JD, Zhao X, Capdevila JH, et al. (2002). Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39:690–4.
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Maeda K, Kishimoto W, et al. (2006). Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34:1109–15.
   PubMed Web of Science ®Google Scholar
• Ito K, Brown HS, Houston JB. (2004). Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473–86.
   PubMed Web of Science ®Google Scholar
• Kamiyama E, Yoshigae Y, Kasuya A, et al. (2007). Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes. Drug Metab Pharmacokinet 22:267–75.
   PubMed Web of Science ®Google Scholar
• Karara A, Dishman E, Blair I, et al. (1989). Endogenous epoxyeicosatrienoic acids. Cytochrome P-450 controlled stereoselectivity of the hepatic arachidonic acid epoxygenase. J Biol Chem 264:19822–7.
   PubMed Web of Science ®Google Scholar
• Karara A, Wei S, Spady D, et al. (1992). Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochem Biophys Res Commun 182:1320–5.
   PubMed Web of Science ®Google Scholar
• Kato Y, Mukai Y, Rane A, et al. (2017). The inhibitory effect of telmisartan on the metabolism of arachidonic acid by CYP2C9 and CYP2C8: an in vitro study. Biol Pharm Bull 40:1409–15.
   PubMed Web of Science ®Google Scholar
• Lee CR, North KE, Bray MS, et al. (2007). CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk i Communities (ARIC) study. Pharmacogenet Genomics 17:349–58.
   PubMed Web of Science ®Google Scholar
• Lu T, Katakam PV, VanRollins M, et al. (2001). Dihydroxyeicosatrienoic acids are potent activators of Ca(2+)-activated K(+) channels in isolated rat coronary arterial myocytes. J Physiol (Lond) 534:651–67.
   Google Scholar
• Mukai Y, Toda T, Takeuchi S, et al. (2015). Simultaneous determination method of epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by LC-MS/MS system. Biol Pharm Bull 38:1673–9.
   PubMed Web of Science ®Google Scholar
• Node K, Huo Y, Ruan X, et al. (1999). Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285:1276–9.
   PubMed Web of Science ®Google Scholar
• Noé J, Portmann R, Brun ME, et al. (2007). Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35:1308–14.
   PubMed Web of Science ®Google Scholar
• Oltman CL, Weintraub NL, VanRollins M, et al. (1998). Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 83:932–9.
   PubMed Web of Science ®Google Scholar
• Omata K, Abraham NG, Escalante B, et al. (1992). Age-related changes in renal cytochrome P-450 arachidonic acid metabolism in spontaneously hypertensive rats. Am J Physiol 262:F8–16.
   PubMed Web of Science ®Google Scholar
• Oni-Orisan A, Edin ML, Lee JA, et al. (2016). Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. J Lipid Res 57:109–19.
   PubMed Web of Science ®Google Scholar
• Pawaskar DK, Straubinger RM, Fetterly GJ, et al. (2013). Interactions of everolimus and sorafenib in pancreatic cancer cells. AAPS J 15:78–84.
   PubMed Web of Science ®Google Scholar
• Powell PK, Wolf I, Jin R, et al. (1998). Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther 285:1327–36.
   PubMed Web of Science ®Google Scholar
• Ren S, Zeng J, Mei Y, et al. (2013). Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors. Drug Metab Dispos 41:60–71.
   PubMed Web of Science ®Google Scholar
• Rifkind AB, Lee C, Chang TK, et al. (1995). Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys 320:380–9.
   PubMed Web of Science ®Google Scholar
• Rodenburg EM, Visser LE, Danser AH, et al. (2010). Genetic variance in CYP2C8 and increased risk of myocardial infarction. Pharmacogenet Genomics 20:426–34.
   PubMed Web of Science ®Google Scholar
• Roman RJ. (2002). P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131–85.
   PubMed Web of Science ®Google Scholar
• Rosolowsky M, Campbell WB. (1996). Synthesis of hydroxyeicosatetraenoic (HETEs) and epoxyeicosatrienoic acids (EETs) by cultured bovine coronary artery endothelial cells. Biochim Biophys Acta 1299:267–77.
   PubMed Web of Science ®Google Scholar
• Sacerdoti D, Gatta A, McGiff JC. (2003). Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat 72:51–71.
   PubMed Web of Science ®Google Scholar
• Schwartzman ML, Martasek P, Rios AR, et al. (1990). Cytochrome P450-dependent arachidonic acid metabolism in human kidney. Kidney Int 37:94–9.
   PubMed Web of Science ®Google Scholar
• Senda A, Mukai Y, Toda T, et al. (2015). Effects of angiotensin II receptor blockers on metabolism of arachidonic acid via CYP2C8. Biol Pharm Bull 38:1975–9.
   PubMed Web of Science ®Google Scholar
• Senda A, Mukai Y, Hayakawa T, et al. (2017). Angiotensin II receptor blockers inhibit the generation of epoxyeicosatrienoic acid from arachidonic acid in recombinant CYP2C9, CYP2J2 and human liver microsomes. Basic Clin Pharmacol Toxicol 121:239–45.
   PubMed Web of Science ®Google Scholar
• Spector AA, Norris AW. (2007). Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 292:C996–C1012.
   PubMed Web of Science ®Google Scholar
• Stangier J, Su CA, Roth W. (2000). Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 28:149–67.
   PubMed Web of Science ®Google Scholar
• Takashima T, Hashizume Y, Katayama Y, et al. (2011). The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [11C]telmisartan. Mol Pharm 8:1789–98.
   PubMed Web of Science ®Google Scholar
• Tornio A, Pasanen MK, Laitila J, et al. (2005). Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol 97:104–8.
   PubMed Web of Science ®Google Scholar
• Transon C, Leemann T, Dayer P. (1996). In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 50:209–15.
   PubMed Web of Science ®Google Scholar
• Tse FL, Jaffe JM, Troendle A. (1992). Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 32:630–8.
   PubMed Web of Science ®Google Scholar
• Wu S, Moomaw CR, Tomer KB, et al. (1996). Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460–8.
   PubMed Web of Science ®Google Scholar
• Wu S, Chen W, Murphy E, et al. (1997). Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272:12551–9.
   PubMed Web of Science ®Google Scholar
• Yasar U, Bennet AM, Eliasson E, et al. (2003). Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 13:715–20.
   PubMedGoogle Scholar
• Zeldin DC, Kobayashi J, Falck JR, et al. (1993). Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem 268:6402–7.
   PubMed Web of Science ®Google Scholar
• Zeldin DC, Moomaw CR, Jesse N, et al. (1996). Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 330:87–96.
   PubMed Web of Science ®Google Scholar
• Zeldin DC. (2001). Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276:36059–62.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Song S, Yang F, et al. (2001). Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther 299:426–33.
   PubMed Web of Science ®Google Scholar
• Zhao L, Wientjes MG, Au JL. (2004). Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 10:7994–8004.
   PubMed Web of Science ®Google Scholar